EP Patent

EP0411660A1 — Antitumor antibiotic BU-4061T

Assigned to Bristol Myers Squibb Co · Expires 1991-02-06 · 35y expired

What this patent protects

A new antibiotic designated BU-4061T is produced by fermentation of actinomycete strain Q996-17 (ATCC-53904). The BU-4061T antibiotic exhibits both in vitro and in vivo antitumor activity. Its structure:

USPTO Abstract

A new antibiotic designated BU-4061T is produced by fermentation of actinomycete strain Q996-17 (ATCC-53904). The BU-4061T antibiotic exhibits both in vitro and in vivo antitumor activity. Its structure:

Drugs covered by this patent

Patent Metadata

Patent number
EP0411660A1
Jurisdiction
EP
Classification
—
Expires
1991-02-06
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.